Phil Garner’s Post

What's shaping the agenda for market access? This article from The Evidence Base® explores some of the current trends as well as issues and challenges faced by the access & pricing function. It was great to see our very own Nick Proctor sharing his views on price vs. value as part of the piece.   Read in full here: https://lnkd.in/emfQrQZh #healtheconomics #pharma #biopharma #healthpolicy #MarketAccess

IQVIA Institute’s Global Trends in R&D 2024 Report. This year’s annual report shows that industry and investors continue to see tremendous value in the vast array of ongoing research programs around the world. The report includes coverage of: 🧪The trends in new drug launches and the overall number of initiated clinical trials 🧪The state of R&D funding and the activity of companies of different types. 🧪The Clinical Development Productivity Index. 🧪Several enablers of R&D productivity. Download the full report here:  https://bit.ly/3vlkVGA #Pipeline Link #ArkPatentIntelligence #PharmaDeals #NewProductIntelligence #RandDTrends #LifeSciences #Healthcare #GlobalHealth

The final session of the GetReal Institute Conference 2024, moderated by Niklas Hedberg, brought together a diverse panel of stakeholders to reflect on the event’s key discussions. The panel outlined priorities for advancing the use of #RWD and #RWE in health care, emphasizing collaboration, transparency, and practical actions moving forward. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

Still time to book your place on our 1-hour webinar created for client insight teams! Our experts will share insights from 4 of the presentations showcased as part of Lumanity's recent internal Research Festival. Learn more and register at https://buff.ly/3xCaT51 'The demand for agile and focused research insights comes against a backdrop of growing industry pressures. Staying ahead of the curve not only requires a deep understanding of the intricate interplay of market trends, competitive landscape, and patient needs, but the ability to adapt quickly to changing dynamics.' Presenters include Joel Shopland, Laura Galimam, Mary Stewart, Damian Eade. #Research #Insights #Patients #Pharma #Innovation

Really excited to welcome George Morgan to the team. Read the article below to learn more about Sam & George and the services we can offer you. #PreferenceResearch #OutcomesResearch #HealthEconomics #LifeScience #DigitalHealth #Pharma #Biotech #MedDevice

What clinical and economic evidence do US payers prefer to drive formulary decisions? Join Clare Foy (Director – Global Market Access, Mtech Access) as she interviews colleagues, Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence), on Thursday 24th October at 4.00pm (BST)/5.00pm (CEST)/8.00am (PDT)/11.00am (EDT) about US payer evidence challenges. Register now at: https://lnkd.in/eHgdkyUw In this live webinar, they will explore: ✅ The evolving payer evidence landscape in the US ✅ Preferences for clinical and economic evidence by US payers ✅ Key differences between the US and other global markets with regard to evidence, HEOR and market access ✅ Opportunities and challenges when launching new medicines/medical devices/diagnostics in US ✅ Innovative perspectives on evidence planning and strategy for the US market ✅ US payers’ perspectives with exclusive insights from Petauri Evidence’s 2024 US payer survey Learn more at https://lnkd.in/eDty3bXf If you're unable to join us live, please register and we will send you a link to the recording shortly after the webinar airs: https://lnkd.in/eHgdkyUw #marketaccess #evidence #payerevidence #USpayers #pharma #medtech #pharmaceutical #GlobalWhispers

When a rapidly growing pharma company faced new competition, it turned to MMIT for its market access expertise. In this case study, learn how MMIT’s data and understanding of the nuances of payer policy and restriction data and segmenting the payer market helped the company make the best strategic decisions for each account. Download the case study: https://ow.ly/vC1X50R7ZHT. #PatientAccess #HealthcareData #HealthcareInsights #MarketAccess

When a rapidly growing pharma company faced new competition, it turned to MMIT for its market access expertise. In this case study, learn how MMIT’s data and understanding of the nuances of payer policy and restriction data and segmenting the payer market helped the company make the best strategic decisions for each account. Download the case study: https://ow.ly/vC1X50R7ZHT. #PatientAccess #HealthcareData #HealthcareInsights #MarketAccess

What evidence do US payers like to see? Do you have what you need for US launch? Join the Mtech Access and Petauri Evidence teams next Thursday (24th October) for our live webinar. Learn more and register at: https://lnkd.in/eAcuxbRE Don’t miss this opportunity to gain valuable insights, which can help you understand the complex US payer landscape and optimise your market access strategy! #evidence #marketaccess #USpayers #GlobalWhispers #pharma #pharmaceuticals #lifesciences

We are really enjoying presenting clients with tailor-made results of the 2024 So What? Research Survey of Australian Doctors, discussing the feedback from GPs or Specialists in their particular area of interest. Get in touch if you’re curious about what your stakeholders are saying and we can create a presentation specific to your team. #pharma #marketresearch